Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2002-02-15
2008-09-23
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S143100, C424S145100, C424S156100, C514S002600, C514S012200, C530S350000, C530S388220
Reexamination Certificate
active
07427403
ABSTRACT:
This invention relates to compositions and methods comprising “lymphotoxin-β receptor blocking agents”, which block lymphotoxin-β receptor signalling. Lymphotoxin-β receptor blocking agents are useful for treating lymphocyte-mediated immunological diseases, and more particularly, for inhibiting Th1 cell-mediated immune responses. This invention relates to soluble forms of the lymphotoxin-β receptor extracellular domain that act as lymphotoxin-β receptor blocking agents. This invention also relates to the use of antibodies directed against either the lymphotoxin-β receptor or its ligand, surface lymphotoxin, that act as lymphotoxin-β receptor blocking agents. A novel screening method for selecting soluble receptors, antibodies and other agents that block LT-β receptor signalling is provided.
REFERENCES:
patent: 5082783 (1992-01-01), Ernst et al.
patent: 5661004 (1997-08-01), Browning et al.
patent: 5670149 (1997-09-01), Browning et al.
patent: 5795964 (1998-08-01), Browning et al.
patent: 5925351 (1999-07-01), Browning et al.
patent: 6312691 (2001-11-01), Browning et al.
patent: 6403087 (2002-06-01), Browning et al.
patent: 6669941 (2003-12-01), Browning et al.
patent: 7001598 (2006-02-01), Browning et al.
patent: 7030080 (2006-04-01), Browning et al.
patent: 2002/0197254 (2002-12-01), Browning et al.
patent: 2004/0198635 (2004-10-01), Browning et al.
patent: 2005/0281811 (2005-12-01), Browning et al.
patent: 0509553 (1992-10-01), None
patent: WO-92/00329 (1992-01-01), None
patent: WO-94/04679 (1994-03-01), None
patent: WO-94/13808 (1994-06-01), None
patent: WO-96/22788 (1996-08-01), None
Crowe, et al Science 264: 707-710, 1994 ‘A lymphotoxin-b-receptor’.
Mohler, et al J. Immunol. 151: 1548-1561, 1993 ‘Soluble TNF receptors are effective therapeutic agents in lethal endotoxemia and function simulatneously as both TNF carriers and TNF antagonists’.
Gommerman et al., Nature Rev. Immunology, vol. 3, No. 8, Aug. 2003, pp. 642-655.
Ruddle, Nancy H. et al, “An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis,”J. Med. Med., vol. 172:1193-1200 (1990).
Androlewicz, Matthew J. et al., “Lymphotoxin is Expressed as a Heteromeric Complex with a Distinct 33-kDa Glycoprotein on the Surface of an Activated Human T Cell Hybridoma,”J. of Biol. Chem., vol. 267(4):2542-2547 (1992).
Arulanandam, Antonio R.N. et al., “A Soluble Multimeric Recombinant CD2 Protein Identifies CD48 as a Low Affinity Ligand for Human CD2: Divergence of CD2 Ligands during the Evolution of Humans and Mice,”J. of Exp. Med., vol. 177:1439-1450 (1993).
Baens, M. et al., “Construction and Evaluation of a hncDNA Library of Human 12p Transcribed Sequences Derived from a Somatic Cell Hybrid,”Genomics, vol. 16(1):214-218 (1993).
Browning, J.L. et al., “Lymphotoxin and an Associated 33-kDa Glycoprotein are Expressed on the Surface of an Activated Human T Cell Hybridoma,”J. of Immunol., vol. 147(4):1230-1237 (1991).
Browning, J.L. et al., “Characterization of Surface Lymphotoxin Forms. Use of specific monoclonal antibodies and soluble receptors,”J. of Immunol., vol. 154(1):33-46 (1995).
Browning, J.L. et al., “Lymphotoxin Beta, a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface,”Cell, vol. 72(6):847-856 (1993).
Browning, J. et al., “Studies of the Differing Effects of Tumor Necrosis Factor and Lymphotoxin on the Growth of Several Human Tumor Lines,”J. of Immunol., vol. 143(6):1859-1867 (1989).
Cher, D.J. et al., “Two Types of Murine Helper T Cell Clone. II. Delayed-type hypersensitivity is mediated by TH1 clones,”J. of Immunol., vol. 138(11):3688-3694 (1987).
Chisholm, P.L. et al., “Monoclonal antibodies to the integrin Alpha-4 subunit inhibit the murine contact hypersensitivity response,”Eur. J. Immunol., vol. 23(3):682-688 (1993).
Crowe et al., “Production of lymphotoxin (LT alpha) and a soluble dimeric form of its receptor using the baculovirus expression system,”J. Immunol. Methods, vol. 168(1):79-89 (1994).
Crowe, P.D. et al., “A Lymphotoxin-Beta Specific Receptor,”Science, vol. 264(5159):707-710 (1994).
Fägerstam et al., “Surface Plasmon Resonance Detection in Affinity Technologies: BIAcore,”Handbook of Affinity Chromatography, Toni Kline, Editor, vol. 63, pp. 229-252 (1993).
Huang, S. et al., “Immune Response in Mice that Lack the Interferon-gamma Receptor,”Science, vol. 259(5102):1742-1745 (1993).
Katz, J.D. et al., “T Helper Cell subsets in Insulin-Dependent Diabetes,”Science, vol. 268(5214):1185-1188 (1995).
Lane, P. et al., “Activated human T Cells express a ligand for the human B cell-associated antigen CD40 which participates in T cell-dependent activation of B lymphocytes,”Eur. J. Immunol., vol. 22(10):2573-2578 (1992).
Lawton, P. et al., “Characterization of the Mouse Lymphotoxin-beta Gene,”J. of Immunol., vol. 154(1):239-246 (1995).
Ling, L.E. et al., “Human Type I Interferon Receptor, IFNAR, Is a Heavily Glycosylated 120-130 kD Membrane Protein,”J. Interferon and Cytokine Res., vol. 15(1):55-61 (1995).
Morrissey, Philip J. et al., “CD4+ T Cells That Express High Levels of CD45RB Induce Wasting Disease When Transferred into Congenic Severe Combined Immunodeficient Mice. Disease Development Is Prevented by Cotransfer of Purified CD4+ T Cells,”J. Exp. Med., vol. 178:237-244 (1993).
Morrison, S.L. et al,. “In Vitro Antibodies: Strategies for Production and Application,”Ann. Rev. Immunol., vol. 10:238-265 (1992).
Modlin, R.L. et al., “Type 2 cytokines and negative immune regulation in human infections,”Current Opinion in Immunol., vol. 5(4):511-517 (1993).
Powrie, F. et al., “Phenotypically distinct subsets of CD4+ T Cells Induce or Protect from Chronic intestinal inflammation in C. B-17 scid mice,”International Immunology, vol. 5(11):1461-1471 (1993).
Powrie, F. et al., “Inhibition of Th1 Responses Prevents Inflammatory Bowel Disease in scid Mice Reconstituted with CD45RBhi CD4+ T Cells,”Immunity, vol. 1(7):553-562 (1994).
Queen, Cary et al., “A humanized antibody that binds to the interleukin 2 receptor,”Proc. Natl. Acad. Sci. U.S.A., vol. 86:10029-10033 (1989).
Reed, S.G. et al., “T-cell and cytokine responses in leishmaniasis,”Current Opinion in Immunol., vol. 5(4):524-531 (1993).
Renshaw, Blair R. et al., “Humoral Immune Responses in CD40 Ligand-deficient mice,”J. Exp. Med., vol. 180:1889-1900 (1994).
Roitt et al., “Hypersensitivity—Type I-IV,”Immunology, Mosby-Year Book Europe Ltd., 3rd ed., pp. 19.1-22.12 (1993).
Romagnani, S., “Lymphokine Production by Human T Cells in Disease States,”Ann. Rev. Immunol., vol. 12:227-257 (1994).
Sayegh, Mohamed H. et al., “CD28-B7 Blockade after Alloantigenic Challenge In Vivo Inhibits Th1 Cytokines by Spares Th2,”J. Exp. Med., vol. 181:1869-1874 (1995).
Traunecker, A. et al., “Highly Efficient Neutralization of HIV with recombinant CD4-immunoglobulin molecules,”Nature, vol. 339(6219):68-70 (1989).
van Dullemen, H.M. et al., “Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2),”Gastroenterology, vol. 109(1):129-135 (1995).
Ware, C.F. et al., “The Ligands and Receptors of the Lymphotoxin System,”Current Topics Microbiol. Immunol., vol. 198:175-218 (1995).
Zhou, M. et al., “Real-Time Measurements of Kinetics of EGF Binding to Soluble EGF Receptor Monomers and Dimers Support the Dimerization Model for Receptor Activation,”Biochemistry, vol. 32(32):8193-8198 (1993).
Benjamin Christopher D.
Browning Jeffrey L.
Hochman Paula S.
Biogen Idec MA Inc.
Lahive & Cockfield LLP
Mandragouras Esq. Amy E.
O'Hara Eileen B.
Williams, Esq. Megan E.
LandOfFree
Methods for inhibiting lymphotoxin β receptor signalling does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for inhibiting lymphotoxin β receptor signalling, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting lymphotoxin β receptor signalling will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3967661